Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Japan / NCT07666217
Active, not recruiting Observational

CoSMAP Trial: SP-EA vs MP-TA Robot-Assisted Radical Prostatectomy

NCT07666217 · tracked via the Priya Life Science Japan tracker
Sponsor
Intuitive Surgical
Phase
Observational
Started
2026-03-26
Last updated
2026-09-17

Condition(s) studied

Prostate Cancer

Study summary

This multicenter retrospective observational study aims to compare perioperative and postoperative outcomes between the da Vinci SP extraperitoneal approach (SP-EA) and the robotic multi-port transperitoneal approach (MP-TA) in robot-assisted radical prostatectomy for localized prostate cancer.

Eligibility

Sex
MALE
Min age
—
Max age
—
Healthy volunteers
No
Inclusion Criteria: 1. Patients with localized prostate cancer (clinical stage T1-T3a, N0, M0) eligible for radical prostatectomy 2. Patients who underwent RARP via SP-EA or MP-TA on or after January 1, 2023 3. Patients with available postoperative follow-up data for ≥6 months (≥166 days) \*note 1) Exclusion Criteria: 1. Patients who have expressed an intention to refuse the use of their data for this study 2. Patients who underwent RARP using surgical approaches other than those specified in the inclusion criteria (e.g., transvesical approach) 3. Patients who underwent RARP with pelvic lymph node dissection (PLND) 4. Patients with a history of radiotherapy for prostate cancer 5. Any other patients whom the principal investigator or a co-investigator deem inappropriate, such as those with missing outcome data.

Primary outcome measure(s)

  • Incidence of postoperative complications and Clavien-Dindo Grade 3a or higher postoperative complications — Within 6 and 12 months after surgery
    Postoperative complications occurring after robot assisted radical prostatectomy, including complications classified as Clavien-Dindo Grade 3a or higher.
  • Urinary continence rate — Within 6 and 12 months after surgery
    Achievement of urinary continence after robot assisted radical prostatectomy.

Trial sites (8)

FacilityCityRegionStatus
Ichinomiyanishi Hospital Ichinomiya Aichi-ken
Fujita Health University Hospital Toyoake Aichi-ken
Saiseikai Yokohamashi Tobu Hospital Yokohama Kanagawa
Kyoto City Hospital Kyoto Kyoto
Mie University Hospital Tsu Mie-ken
Ageo Central General Hospital Ageo Saitama
National Cancer Center Hospital Tokyo Tokyo
Tokyo Medical Center Tokyo Tokyo

Other trials for the same condition

A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer Recruiting
A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer Active, not recruiting
Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC) Active, not recruiting
Diagnostic Performance of [18F]PSMA-1007 PET/CT Imaging in Patients With Newly-Diagnosed Prostate Cancer Recruiting
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve. Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07666217 on ClinicalTrials.gov ↗ ← All trials in Japan